Yuflyma Kit
NDC 72606-030
Product Information
Yuflyma (adalimumab-aaty) is a BLA-approved product labeled by Celltrion Usa, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a kit. This product entry covers the primary NDC 72606-030 and 14 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 72606-030?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ADALIMUMAB (UNII: FYS6T7F842)
- ADALIMUMAB (UNII: FYS6T7F842) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2639651 - adalimumab-aaty 40 MG in 0.4 ML Auto-Injector
- RxCUI: 2639651 - 0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector
- RxCUI: 2639651 - adalimumab-aaty 40 MG per 0.4 ML Auto-Injector
- RxCUI: 2639657 - Yuflyma 40 MG in 0.4 ML Auto-Injector
- RxCUI: 2639657 - 0.4 ML adalimumab-aaty 100 MG/ML Auto-Injector [Yuflyma]
* Please review the full disclaimer at the bottom of this page.
Patient Education
Adalimumab Injection
Adalimumab injection products are used alone or with other medications to relieve the symptoms of certain autoimmune disorders (conditions in which the immune system attacks healthy parts of the body and causes pain, swelling, and damage) including the following: rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults, juvenile idiopathic arthritis (JIA; a condition that affects children in which the body attacks its own joints, causing pain, swelling, loss of function, and delays in growth and development) in children 2 years of age and older, Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) that has not improved when treated with other medications in adults and children 6 years of age and older, ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum) when other medications and treatments did not help or could not be tolerated in adults and children 5 years of age and older, ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas causing pain and joint damage) in adults, psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults, hidradenitis suppurativa (a skin disease that causes pimple-like bumps in the armpits, groin, and anal area) in adults and children 12 years of age and older, uveitis (swelling and inflammation of different areas of the eye) in adults and children 2 years of age and older, chronic plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults. Adalimumab injection products are in a class of medications called tumor necrosis factor (TNF) inhibitors. They work by blocking the action of TNF, a substance in the body that causes inflammation.
[Learn More]
* Please review the full disclaimer at the bottom of this page.